ANDA 203133, held by Amneal Pharmaceuticals. Dextromethorphan Polistirex.
As of Nov 21, 2026, ANDA 203133 (Dextromethorphan Polistirex), held by Amneal Pharmaceuticals, was first approved by FDA on Jul 28, 2017, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Uses Temporarily relieves cough due to minor throat and bronchial irritation as may occur with the common cold or inhaled irritants the impulse to cough to help you get to sleep
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 28, 2017 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dextromethorphan PolistirexEQ 30MG HYDROBROMIDE/5ML · suspension, extended release;oral | Dextromethorphan Polistirex | OTC |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters